Search

Since the 21st century, with the rapid development of network information technology, network technology has begun to be widely used in education. Seizing the opportunity of developing new generation information network technology, establishing a broad coverage education informatization system, strengthening the construction and application of network teaching resource system, and accelerating the development and sharing of high-quality educational resources are the current development goals of education informatization. The open sharing platform of physical education curriculum resources based on MOOC network is an important way to “promote the construction, popularization, and sharing of high-quality physical education resources”. The open-sharing platform of teaching course resources based on MOOC network construction and application has increased access to course resources by 10%. It can promote the exchange and sharing of high-quality teaching resources among universities, realize inter-college cooperation and optimal integration of resources, enrich physical education course resources, and promote the overall improvement of the teaching environment. Furthermore, such improvement in physical education teaching mode improves students’ interest, promotes overall physical education development, guarantees the quality of course teaching, and finally enhances the overall teaching level of the school.

In China, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are integral to the antiretroviral therapy (ART) regimen for persons living with HIV (PWH), comprising over 80% of such treatments. To broaden treatment options and improve therapeutic effectiveness, Ainuovirine (ANV), a new NNRTI, was authorized for ART in 2021. Nevertheless, the clinical efficacy of ANV and its impact on blood biochemical markers remain somewhat underexplored. This study seeks to evaluate ANV's clinical performance in ART and its influence on relevant treatment parameters. A retrospective analysis was performed on 208 patients treated with an ANV-based regimen from July 2021 to July 2023, monitoring indicator changes from baseline to week 24. The primary endpoint was the proportion of participants achieving HIV-1 RNA levels of less than 50 copies/mL by week 24. Secondary endpoints involved assessing variations in CD4+ T cell counts and blood biochemical markers from baseline. These outcomes were also compared with data from 241 patients treated with an Efavirenz (EFV)-based regimen in the same time frame. The findings suggest that the ANV-based regimen is as effective as the EFV-based regimen in viral suppression (p >.05) and offers superior improvements in lipid profiles, liver function, and immune system indicators, alongside fewer adverse reactions. These results affirm ANV's efficacy and safety as an antiretroviral therapy option, offering Acquired Immune Deficiency Syndrome patients a wider array of treatment possibilities and the potential for better treatment outcomes. [ABSTRACT FROM AUTHOR]

Introduction: The efficacy and safety of ainuovirine+lamivudine+tenofovir (ANV+3TC+TDF) and efavirenz+lamivudine+tenofovir (EFV+3TC+TDF) have been confirmed in previous clinical trials; however, there are no related studies on patient‐reported outcomes. This study aimed to evaluate the effectiveness and safety of these 2 antiretroviral therapy regimens and to understand the patient's symptom experience and subjective experience of sleep quality through patient‐reported outcomes. Methods: This is a single‐center prospective cohort study with 243 patients evaluated from October 1, 2021 to June 30, 2022. Virological effectiveness and patient‐reported outcomes results were analyzed. The primary endpoint was the proportion of HIV viral load <50 copies/mL (virological suppression rate) at 48 weeks and the changes in the HIV symptom index and Pittsburgh sleep quality index. Results: The virological suppression rates in the ANV+3TC+TDF and EFV+3TC+TDF groups were 83.6% (102/122) and 87.6% (106/121), respectively, at 48 weeks. In the ANV+3TC+TDF group, the scores of HIV symptom index and pittsburgh sleep quality index in the 48th week were lower than the baseline level (p < 0.05). Logistic regression results showed that the baseline regimen EFV+3TC+TDF was a risk factor for dizziness/lightheadedness (odds ratio = 3.153, 95% confidence interval: 1.473–6.748, p = 0.003), sadness/depression odds ratio = 2.404, 95% confidence interval:1.188–4.871, p = 0.015), and difficulty sleeping (odds ratio = 2.802, 95% confidence interval: 1.437–5.463, p = 0.002) at 48 weeks. Conclusions: Both regimens showed good virological effectiveness; however, compared with ANV+3TC+TDF, the EFV+3TC+TDF regimen reduced the prevalence of HIV‐related symptoms. [ABSTRACT FROM AUTHOR]

This study aimed to evaluate the therapeutic effect and tolerance of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) use for 24 weeks in anti-retroviral therapy (ART)-naïve patients in China. This single-center retrospective cohort study included ART-naïve patients who received BIC/FTC/TAF from July 2021 to April 2022. The proportion of patients with HIV RNA < 50 copies/mL at the end point of 24 weeks (virological suppression rate) was the primary outcome, and the changes in CD4 cell count, CD4/CD8 ratio, weight, blood lipid, and safety were secondary outcomes. A total of 80 ART-naïve patients were enrolled. The virological suppression rate was 86.3% at 24 weeks. The median CD4 cell count increased from 212 cells/μL (interquartile range [IQR]: 90.3–398.3) at baseline to 348 cells/μL (IQR: 219.8–541.0) at 24 weeks. The median CD4/CD8 ratio increased from 0.25 (IQR: 0.13–0.37) at baseline to 0.40 (IQR: 0.26–0.66) at 24 weeks. During the follow-up of 80 ART-naïve patients using BIC/FTC/TAF, 16 participants had adverse events; however, these events did not lead to drug withdrawal. This real-world cohort study showed that BIC/FTC/TAF could achieve good immunological and virological responses in ART-naïve patients. In addition, this study also shows good safety. [ABSTRACT FROM AUTHOR]

Trace N, N‐dimethylformamide(DMF) containing composite polymer electrolytes (CPEs) has attracted much attention owing to the dramatically increased Li+‐conductivity. But the amount of DMF is critical and needs to be clarified for the interfacial stability, since DMF is easily reduced by Li‐metal. Herein, the influences of DMF in poly(ethylene oxide) (PEO) and poly(vinylidene fluoride) (PVDF) based CPEs are studied on the Li+‐conductivity and interfacial stability. In PEO‐based CPEs, owing to a stronger interaction of lithium bis(trifluoromethanesulfon)imide (LiTFSI) with PEO than DMF, DMF can not be confined and be easily evaporated off. Only ≈0.25wt.% DMF is absorbed on ceramic electrolyte fillers, giving two times increased Li+‐conductivity compared with the DMF‐free counterparts and generating stable interface with Li‐metal; but over much DMF (≥2.2 wt.%) leads to serious interfacial reactions with Li‐metal. While in PVDF‐based CPEs, ≈8wt.% DMF is confined by LiTFSI owing to a stronger interaction of LiTFSI with DMF than with PVDF. Short‐term stable interface with Li‐metal can be obtained, but longer‐term cycling or higher current density leads to the gradually aggravated reactions with Li‐metal. Thanks to the high‐voltage stability of PVDF based CPEs, better cycling performance is obtained when they are used as catholytes to match high‐voltage cathodes. [ABSTRACT FROM AUTHOR]